Skip to main content

Genetic Profiles Linked to Hematologic Outcomes

February 2012 Vol 5, No 1, Special Issue - Conference Highlights ASH

Hematologic malignancies are characterized by genetic subtypes with varying prognoses. Analysis of these subtypes is beginning to make a difference in the clinic.

“Researchers are finding that genetic determinants are important causes of treatment failure,” said Kathryn Roberts, MD, who presented the findings from St. Jude Children’s Research Hospital in Memphis.

“But it is currently not possible to increase the dose or intensity of current therapies because of toxicity,” Dr Roberts said.

The findings support the screening of all patients newly diagnosed with acute lymphocytic leukemia (ALL) for the presence of high-risk subtypes. Identifying these patients should help characterize the genetic abnormalities that underlie a unique subtype of high-risk B-cell ALL and also help select candidates for targeted therapies.

Dr Roberts and her colleagues have identified a unique subtype of BCR-ABL–negative, high-risk B-cell ALL, with a deletion or mutation of IKZF1, which confers a poor outcome. They refer to this new subtype as “Ph [Philadelphia chromosome]-like ALL.” Up to 15% of pediatric ALL cases can be classified as Ph-like, and previous trials have shown that the outcome of these cases can be improved when tyrosine kinase inhibitors such as imatinib are added to chemotherapy regimens.

“This study represents potential changes in care,” said Martin S. Tallman, MD, Chief of Leukemia Services, Memorial Sloan-Kettering Cancer Center, New York, who moderated a press briefing. “This study provides further evidence that we can target specific leukemias with directed therapy, rather than just continue to give relatively indiscriminate chemotherapy.”

For Lymphoma, Genetic Risk Score Predicts Outcome
In patients with diffuse large B-cell lymphoma (DLBCL), a genetic risk score based on the expression of a small number of genes was able to predict clinical outcomes related to specific treatments, investigators from the Eastern Cooperative Oncology Group (ECOG) and Southwest Oncol­ogy Group reported.

Using tissue from 183 DLBCL patients in the ECOG E4494 phase 3 trial, researchers were able to construct a 5-gene predictor model that identified outcomes of patients treated with CHOP (cyclophosphamide/ doxorubicin/vincristine/prednisolone) and a 6-gene model that was predictive in patients treated with R-CHOP (CHOP plus rituximab). High-versus-low genetic risk scores significantly predicted clinical outcomes at a median follow-up of 9.4 years, reported Jane Winter, MD, of the Lymphoma Committee, ECOG, Chicago, IL.

Related Items
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on February 25, 2020 in Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Videos published on January 5, 2016 in Conference Highlights ASH
Real-World Data on Primary Treatment for Mantle-Cell Lymphoma 2000-2011 – A Nordic Lymphoma Group Observational Study
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Oral Arsenic Trioxide-Based Regimen as Salvage Treatment for Relapsed or Refractory Mantle-Cell Lymphoma
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma in Need of Palliative Therapy
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Last modified: August 30, 2021